News | August 25, 2011

Radiation Therapy Oncology Group Awards US Oncology Research Full Member Status

August 25, 2011 — US Oncology Research (USOR) and Radiation Therapy Oncology Group (RTOG) announced that USOR has earned Full Member status. As a Full Member, USOR has proven to be a leader in radiation clinical trials. The organization is one of fewer than 50 to reach this status.

Since becoming an Affiliate Member of RTOG in 2008, USOR quickly became one of the top accruing members. Its network of oncology practices eventually enrolled more patients in RTOG trials than any other member. In 2010, RTOG announced USOR ranked number one in patient accruals, surpassing all affiliate and full RTOG members.

All together, network physicians have enrolled 163 patients into RTOG clinical trials held at community-based oncology practices. This allows patients to receive cutting-edge radiation clinical trials in their hometowns.

"US Oncology Research has been an outstanding Affiliate Member, and we're excited to award the network Full Member status. We at RTOG are very pleased that US Oncology Research achieved full member status as quickly as they did," said Walter J Curran, Jr., M.D., chairman, RTOG group chairman and executive director of the Winship Cancer Institute of Emory University. "Their commitment to providing the infrastructure to accrue large numbers of patients into clinical trial research from community-based practices will not only benefit their patients, it will also help us answer our research questions faster, and that will benefit all cancer patients."

Radiation oncology-focused clinical trials offer cancer patients integrated and unique therapies that can provide a better chance for survival. Clinical trials in cancer care, whether focused on chemotherapy, radiation or other treatment methods, seek improvement upon standard treatment, so each patient has the best opportunity for a positive outcome.

"We are making great strides in a concentration that is quite unique," said Vivek Kavadi, M.D., medical director of radiation oncology for US Oncology and radiation oncologist with Texas Oncology-Sugar Land. "Having radiation oncology clinical trials available in local communities is crucial for our patients. They are able to participate in integrated, radiation-focused clinical trials that are truly state-of-the-art."

There are 19 RTOG approved sites affiliated with USOR. These community-based practices are located across the country and had 91 accruals in 2010. USOR averages eight accruals per month.

In order to remain an RTOG Full Member, the membership evaluation committee, according to the RTOG membership evaluation policy and the group bylaws, must evaluate USOR yearly.

Based in Philadelphia, RTOG is a key clinical research component of the American College of Radiology (ACR) and serves as a multi-institutional, international clinical cooperative group funded primarily by the National Cancer Institute (NCI).

For more information: www.usoncology.com or www.rtog.org

Related Content

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Cardiac Imaging | April 25, 2019
The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Gamma Knife radiosurgery has become the preferred radiation therapy option for patients with brain tumors at facilities like the Northwestern Medicine Cancer Center, pictured here

Gamma Knife radiosurgery has become the preferred radiation therapy option for patients with brain tumors at facilities like the Northwestern Medicine Cancer Center, pictured here. The technology is favored largely for its ability to precisely target tumors while sparing healthy tissue.

Feature | Radiation Oncology | April 11, 2019 | By Jeff Zagoudis
Brain tumors are some of the most complicated forms of cancer to treat due to their extremely sensitive location.
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...